

NOF CORPORATION

DDS DEVELOPMENT DIVISION
YEBISU GARDEN PLACE TOWER
20-3, EBISU 4-CHOME, SHIBUYA-KU, TOKYO 150-6019 JAPAN
TEL. +81-3-5424-6741 FAX. GIII +81-3-5424-6769



June, 2021

ON-DEMAND TALK AT CRS 2021 ANNUAL MEETING -VIRTUAL- (JULY 25-29)

NOF CORPORATION will present NOF DDS technology for mRNA Vaccines at **CRS 2021 ANNUAL MEETING -VIRTUAL-** to be held from **July 25 to 29, 2021**.

Conference Website: <https://2021.controlledreleasesociety.org/>

Presentation Title: Interaction of LNP-mRNA Vaccines with Immune Effector Cells: Implications for Development of a Single Dose mRNA Vaccine

Abstract:

Messenger RNA based vaccines delivered with lipid nanoparticles have recently emerged as a leading strategy for treatment of infectious disease including COVID-19. One major drawback of the two current approved vaccines is that they require two doses to achieve a full antibody response. Here we characterize immune responses to a novel biodegradable lipid platform, COATSOME[®] SS-Lipid, for mRNA vaccines. We showed evidence of robust T-cell responses with a single shot mRNA-LNP vaccine, consistent with presentation of exogenous mRNA antigens in the MHC-I complex. Our current efforts are focused on creating improved LNP systems for targeting of dendritic cells to enable single dose mRNA vaccines.

On-Demand Talk will be available for viewing starting 2 weeks before the conference.

Please contact our regional offices below for the detail of the presentation or if you have any questions about the contents of the presentation.

[Americas]

NOF AMERICA CORPORATION
E-mail: info@nofamerica.com
Tel: NY Office: +1-914-681-9790
CA Office: +1-650-993-7375

[Europe]

NOF EUROPE GmbH
E-mail: info@nofeurope.com
Tel: +49-69-7706-100-0

[Asia Pacific, Japan]

NOF CORPORATION
DDS Development Division
E-mail: ddsinfo@nof.co.jp

[China]

NOF (Shanghai) Co. Ltd.
E-mail: info@nof.cn
Tel: +86-21-6210-1100